The vaccine will protect infants from diphtheria, tetanus, whooping cough and Hib-Meningitis in India, Panacea Biotec said in a filing to BSE.
The product being fully liquid requires no reconstitution, saves time and minimises chances of error, it added.
Panacea Biotec Joint Managing Director Rajesh Jain said: "Panacea Biotec will remain committed to its mission 'Innovation in support of Life' and continue to provide the latest and most affordable preventive and therapeutic care to patients across the globe."
The stock of Panacea Biotec was today trading at Rs 120.50 in the morning trade on BSE, up 4.87 per cent from its previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
